We are live on ! Find out more
TCM

Tamarack Capital Management Portfolio holdings

AUM $840M
1-Year Est. Return 19.47%
This Fund
S&P 500
This Quarter Est. Return
+5.78%
1 Year Est. Return
+19.47%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$759M
AUM Growth
+$99.7M
Cap. Flow
+$68.3M
Cap. Flow %
9%
Top 10 Hldgs %
62.14%
Holding
49
New
10
Increased
19
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$13.1M
2
KERX
Keryx Biopharmaceuticals Inc
KERX
+$12.2M
3
BDX icon
Becton Dickinson
BDX
+$9.18M
4
TECH icon
Bio-Techne
TECH
+$7.13M
5
TMO icon
Thermo Fisher Scientific
TMO
+$6.45M

Top Sells

Rank Stock Value
1
DGX icon
Quest Diagnostics
DGX
+$12.9M
2
MYGN icon
Myriad Genetics
MYGN
+$10.2M
3
HNGR
Hanger Inc.
HNGR
+$8.31M
4
NTUS
Natus Medical Inc
NTUS
+$8.04M
5
DXCM icon
DexCom
DXCM
+$6.95M

Sector Composition

Rank Sector Weight
1 Healthcare 58.29%
2 Technology 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRGA
26
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$9.88M 1.3%
66,667
-574
-0.9% -$87.4K
OREX
27
DELISTED
Orexigen Therapeutics, Inc.
OREX
$7.83M 1.03%
+100,000
New +$6.2M
TMO icon
28
Thermo Fisher Scientific
TMO
$213B
$6.72M 0.89%
+50,000
New +$6.45M
OXFD
29
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$6.37M 0.84%
+452,133
New +$6.15M
IMPR
30
DELISTED
IMPRIVATA, INC COM
IMPR
$6.01M 0.79%
429,261
+51,337
+14% +$708K
MDXG icon
31
CALL
MiMedx Group
MDXG
$614M
$5.2M 0.69%
500,000
-75,300
-13% -$705K
CORI
32
DELISTED
Corium International, Inc.
CORI
$5.1M 0.67%
778,921
+28,821
+4% +$197K
RMD icon
33
PUT
ResMed
RMD
$32.4B
$4.31M 0.57%
+60,000
New +$3.9M
STRM
34
DELISTED
Streamline Health Solutions
STRM
$4.04M 0.53%
75,867
– –
ICUI icon
35
ICU Medical
ICUI
$4.14B
$3.26M 0.43%
35,000
+21,125
+152% +$1.85M
FEIC
36
DELISTED
FEI COMPANY
FEIC
$2.69M 0.35%
+35,180
New +$2.82M
HNGR
37
DELISTED
Hanger Inc.
HNGR
$2.27M 0.3%
100,000
-354,501
-78% -$8.31M
STE icon
38
Steris
STE
$22.5B
$703K 0.09%
+10,000
New +$660K
WINT
39
DELISTED
Windtree Therapeutics Inc
WINT
$280K 0.04%
16,824
-90,319
-84% -$1.78M
BSX icon
40
PUT
Boston Scientific
BSX
$71.3B
– –
-275,000
Closed -$3.64M
IWM icon
41
CALL
iShares Russell 2000 ETF
IWM
$82.1B
– –
-250,000
Closed -$29.9M
LAB icon
42
Standard BioTools
LAB
$307M
– –
-24,442
Closed -$824K
MYGN icon
43
Myriad Genetics
MYGN
$296M
– –
-300,000
Closed -$10.2M
PFE icon
44
CALL
Pfizer
PFE
$148B
– –
-474,300
Closed -$14M
PM icon
45
PUT
Philip Morris
PM
$294B
– –
-150,000
Closed -$12.2M
TRIB
46
Trinity Biotech
TRIB
$7.88M
– –
-833
Closed -$2.19M
NTUS
47
DELISTED
Natus Medical Inc
NTUS
– –
-223,236
Closed -$8.04M
XENT
48
DELISTED
Intersect ENT, Inc
XENT
– –
-18,149
Closed -$337K
CFN
49
DELISTED
CAREFUSION CORPORATION
CFN
– –
-78,500
Closed -$4.66M
1
2

Similar funds

RI
Relational Investors San Diego, California $840M AUM 0.57% 1-Year Est. Return
CWA
Constellation Wealth Advisors New York $903M AUM 2.38% 1-Year Est. Return
GHF
Good Harbor Financial Barrington, Illinois $916M AUM 5.96% 1-Year Est. Return
F
FutureAdvisor San Francisco, California $617M AUM 6.57% 1-Year Est. Return
TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
BMCMI
Bryn Mawr Capital Management Inc Bryn Mawr, Pennsylvania $577M AUM 6.5% 1-Year Est. Return
GACM
Green Arrow Capital Management New York $535M AUM 14.21% 1-Year Est. Return
AH
Achievement Holdings Chicago, Illinois $1.2B AUM 9.2% 1-Year Est. Return

Tamarack Capital Management's Q1 2015 Portfolio in Review

As of Q1 2015, Tamarack Capital Management held 49 positions worth $759M, up 15% from $659M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Tamarack Capital Management deployed $68.3M of net new capital in Q1 2015, opening 10 new positions and adding to 19 existing holdings. Its largest new stake was Pfizer: 412,323 shares worth $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 59% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Quest Diagnostics, an estimated $12.9M trimmed.

  • Tamarack Capital Management's largest Q1 2015 buy was Pfizer: 412,323 shares worth $13.6M.
  • Tamarack Capital Management added most to Becton Dickinson in Q1 2015, an estimated $9.18M increase.
  • Tamarack Capital Management's biggest Q1 2015 reduction was Quest Diagnostics, cutting an estimated $12.9M.
  • Tamarack Capital Management fully exited Myriad Genetics in Q1 2015, selling an estimated $10.2M.
  • Tamarack Capital Management's ten largest holdings make up 62% of its $759M portfolio in Q1 2015.
  • Tamarack Capital Management opened 10 new positions and closed 10 in Q1 2015.
  • Tamarack Capital Management's portfolio value rose 15% quarter-over-quarter to $759M.

Based on Tamarack Capital Management's 13F filing for Q1 2015, filed 11 May 2015.